Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$18.15
-0.8%
$14.99
$7.75
$19.93
$138.67M0.6227,494 shs15,693 shs
Anteris Technologies Global Corp. stock logo
AVR
Anteris Technologies Global
$3.80
+2.4%
$4.29
$2.34
$8.79
$137.03MN/A293,471 shs209,036 shs
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$2.16
-0.7%
$1.64
$0.73
$3.90
$136.39M0.7410,718 shs239,497 shs
Relay Medical Corp. stock logo
RYMDF
Relay Medical
$0.01
$0.01
$0.13
$0.72
$2.07M1.1568,743 shsN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
0.00%+4.85%+11.76%+110.31%+37.40%
Anteris Technologies Global Corp. stock logo
AVR
Anteris Technologies Global
0.00%-6.40%-19.83%+31.03%+379,999,900.00%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
0.00%-7.51%+63.26%+62.64%+4.61%
Relay Medical Corp. stock logo
RYMDF
Relay Medical
0.00%0.00%-27.46%-55.42%-57.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
3.666 of 5 stars
3.33.00.04.71.80.00.0
Anteris Technologies Global Corp. stock logo
AVR
Anteris Technologies Global
N/AN/AN/AN/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
1.6427 of 5 stars
3.50.00.00.02.81.70.0
Relay Medical Corp. stock logo
RYMDF
Relay Medical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.67
Moderate Buy$33.0081.82% Upside
Anteris Technologies Global Corp. stock logo
AVR
Anteris Technologies Global
3.00
Buy$16.50334.21% Upside
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
3.00
Buy$6.00178.42% Upside
Relay Medical Corp. stock logo
RYMDF
Relay Medical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RYMDF, ASMB, GALT, and AVR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$28.52M4.86N/AN/A$5.25 per share3.46
Anteris Technologies Global Corp. stock logo
AVR
Anteris Technologies Global
$2.70M50.75N/AN/A$1.74 per share2.18
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.68) per shareN/A
Relay Medical Corp. stock logo
RYMDF
Relay Medical
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$40.18M-$6.23N/AN/AN/A-124.15%-131.77%-36.81%8/6/2025 (Estimated)
Anteris Technologies Global Corp. stock logo
AVR
Anteris Technologies Global
-$76.29MN/A0.00N/AN/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)
Relay Medical Corp. stock logo
RYMDF
Relay Medical
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest RYMDF, ASMB, GALT, and AVR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.20-$0.15+$0.05-$0.15N/AN/A
5/13/2025Q1 2025
Anteris Technologies Global Corp. stock logo
AVR
Anteris Technologies Global
N/A-$0.61N/A-$0.61N/AN/A
5/8/2025Q1 2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$2.01-$1.17+$0.84-$1.17$7.41 million$9.42 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Anteris Technologies Global Corp. stock logo
AVR
Anteris Technologies Global
N/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
Relay Medical Corp. stock logo
RYMDF
Relay Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
2.05
2.05
Anteris Technologies Global Corp. stock logo
AVR
Anteris Technologies Global
N/A
3.67
3.65
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
0.08
0.08
Relay Medical Corp. stock logo
RYMDF
Relay Medical
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
1007.64 million7.25 millionOptionable
Anteris Technologies Global Corp. stock logo
AVR
Anteris Technologies Global
13836.06 millionN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
963.29 million31.58 millionOptionable
Relay Medical Corp. stock logo
RYMDF
Relay Medical
N/A241.20 millionN/ANot Optionable

Recent News About These Companies

Relay Advancing Mutant PI3Kα Inhibitor into Phase III Breast Cancer Trial
Relay For Life ambassador sharing story of cancer fight
BC Relay for Life goes on

New MarketBeat Followers Over Time

Media Sentiment Over Time

Assembly Biosciences stock logo

Assembly Biosciences NASDAQ:ASMB

$18.15 -0.15 (-0.82%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$18.07 -0.08 (-0.44%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Anteris Technologies Global stock logo

Anteris Technologies Global NASDAQ:AVR

$3.80 +0.09 (+2.43%)
As of 07/3/2025 01:00 PM Eastern

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$2.15 -0.02 (-0.69%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$2.22 +0.06 (+2.78%)
As of 08:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Relay Medical stock logo

Relay Medical OTCMKTS:RYMDF

$0.0086 0.00 (0.00%)
As of 07/3/2025

Relay Medical Corp. operates as a medical technology company, which engages in the development of novel medical devices for in vitro diagnostics and point-of-care testing. Its platform technologies include HemoPalm and Pharmatrac. The HemoPalm develops a POCT unit-use cartridge based blood analyzer with full enterprise capabilities. The Pharmatrac is an AI and data analytics driven personal medication management system that addresses the growing problem of non-adherence to treatment. The company was founded by James Samsoondar in 2005 and is headquartered in Toronto, Canada.